Acción 300391 CHANGJIANG PHARMACEUTICAL GROUP CO., LTD.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Changjiang Pharmaceutical Group Co., Ltd.

Acciones

300391

CNE100001XN8

Precio de cierre Shenzhen S.E.
Otros sitios de cotización
 00:00:00 30/04/2024 		Varia. Cinco días. Varia. 1 de enero.
4,05 CNY -5,15 % Gráfico intradía de Changjiang Pharmaceutical Group Co., Ltd. +2,02 % -47,67 %
29/04 Changjiang Pharmaceutical Group Co. Resultados del primer trimestre finalizado el 31 de marzo de 2024 CI
29/04 Changjiang Pharmaceutical Group Co. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Yichang Hec Changjiang Pharmaceutical Updates on Possible Merger with Sunshine Lake Pharma
Yichang Hec Changjiang Pharmaceutical's Net Profit Surges in 2023 as Revenue Jumps
YiChang HEC ChangJiang Pharmaceutical's Profit Surges in 2023
Yichang Hec Changjiang Pharmaceutical Expects Up to 2,627% Profit Surge in 2023
HEC ChangJiang Pharmaceutical Increases Transaction Limits Under 2 Contracts
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
HEC ChangJiang Pharmaceutical's Insulin Injection Cleared for Market Launch in China
HEC ChangJiang Pharmaceutical Returns to Profit on Surge in Anti-Viral Drug Sales
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
China Greenlights New Drug Application for HEC ChangJiang Pharmaceutical's Hepatitis C Drug
HEC ChangJiang Pharmaceutical Forecasts Surge in H1 Profit; Shares Rise 5%
Yucong Tianshun No. 2 Private Equity Securities Investment Fund managed by Shanghai Yucong Asset Management Co., Ltd completed the acquisition of 5.9942% stake in Changjiang Pharmaceutical Group Co., Ltd. from Changxing Shengshi Fenghua Business Co., Ltd.
HEC ChangJiang Pharma Repurchases $400 Million Convertible Bonds Issued to Blackstone
Yucong Tianshun No. 2 Private Equity Securities Investment Fund managed by Shanghai Yucong Asset Management Co., Ltd signed Share Transfer Agreement to acquire 5.9942% stake in Changjiang Pharmaceutical Group Co., Ltd. from Changxing Shengshi Fenghua Business Co., Ltd. for CNY 154.14 million.
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Changjiang Pharma Units Sign 359 Million Yuan Contracts
YiChang HEC ChangJiang Pharma to Return to Profitability
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción 300391
  4. Noticias Changjiang Pharmaceutical Group Co., Ltd.
  5. Otros idiomas